Ключевые слова:
цереброваскулярные заболевания, гомоцистеин, С-реактивный белок, инсульт, дисциркуляторная энцефалопатия, эндотелиальная дисфункция, воспаление, факторы риска.Библиографические ссылки
Feigin V.L., Nguyen G., Cercy K., et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820. doi: 10.1016/S1474-4422(21)00252-0.
Spence J.D., Bang H., Chambless L.E., et al. Vitamin Intervention for Stroke Prevention trial: an efficacy analysis. Stroke. 2005;36(11):2404-2409. doi: 10.1161/01.STR.0000185978.65816.5a.
Ridker P.M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145-148. doi: 10.1161/CIRCRESAHA.1 15.306651.
Stanger O., Semmelrock H.J., Wonisch W., et al. Effects of homocysteine-lowering therapy on endothelial function and inflammation markers in patients with peripheral arterial disease. Atherosclerosis. 2005;182(1):187-193. doi: 10.1016/ j.atherosclerosis.2005.02.019.
Poddar R., Sivasubramanian N., DiBello P.M., et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation. 2001;103 (22):2717-2723. doi: 10.1161/01.CIR.103.22.2717.
Weiss N., Heydrick S., Zhang Y.Y., et al. Cellular redox state and endothelial dysfunction in mild hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 2002;22(6): e18-e22. doi: 10.1161/01.ATV.000 0017140.71456.6D.
Undas A., Brozek J., Jankowski M., et al. Plasma homocysteine and thrombin generation in patients with arterial thrombosis. Pol Arch Med Wewn. 2005;113(5):381-387.
Hofmann M.A., Lalla E., Lu Y., et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107(6):753-759. doi: 10.1172/JCI1 1254.
Upchurch G.R. Jr, Welch G.N., Fabian A.J., et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272(27):17012-17017. doi: 10.107 4/jbc.272.27.17012.
Jacobsen D.W. Homocysteine and vitamins in cardiovascular disease. Clin Chem. 1998;44(8 Pt 2):1833-1843.
Homocysteine Studies Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006;1 51(2):282-287. doi: 10.1016/j.ahj.2005.10.004.
Wang X., Qin X., Demirtas H., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876-1882. doi: 10.1016/S0140-6736(07)60835-X.
Kelly P.J., Rosand J., Kistler J.P., et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 2002; 59(4): 529-535. doi: 10.1212/wnl.59.4. 529.
Seshadri S., Beiser A., Selhub J., et al. Plas-ma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346(7):476-483. doi: 10.1056/NEJMoa011613.
Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest. 2003;111(12): 1805-1812. doi: 10.1172/JCI18921.
Du Clos T.W. Function of C-reactive protein. MAbs. 2013;5(2):129-135. doi: 10.4161/mabs. 23409.
Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18): 2165-2168. doi: 10.1161/01.CIR.102.18.2165.
Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001;103(9): 1194-1197. doi: 10.11 61/01.CIR.103.9.1194.
Venugopal S.K., Devaraj S., Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens. 2005;14(1):33-37. doi: 10.1097 /01.mnh.0000152399.41398.1f.
Cermak J., Key N.S., Bach R.R., et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82(2): 513-520. doi: 10.1182/blood. V82.2. 513.bloodjour-nal822513.
Molloy K.J., Himmelfarb J., Addison C., et al. C-reactive protein induces matrix metalloproteinase-9 expression in human vascular smooth muscle cells. J Investig Med. 2008;56(6):841-848. doi: 10. 2310/JIM.0b013e31817c1e8c.
d'Avila J.C., Lam T.I., Bingham D., et al. Microglial activation induced by brain-derived factors is impaired in aging. J Neuroinflammation. 2018;15 (1):197. doi: 10.1186/s12974-018-1228-5.
Kummer M.P., Heneka M.T. inflammaso-mes and neuroinflammation in Alzheimer's disease. Brain Pathol. 2020;30(2):293-306. doi: 10.1111/b pa.12787.
Emerging Risk Factors Collaboration, Kaptoge S., Di Angelantonio E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140. doi: 10.1016/S0140-6736(09)61717-7.
Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi: 10.1056/NEJ Moa0807646.
Di Napoli M., Godoy D.A., Campi V., et al. C-reactive protein level in the first 24 hours after ischemic stroke is associated with 90-day mortality: a meta-analysis. Int J Stroke. 2018;13(7):731-740. doi: 10.1177/1747493017748750.
Wada-Isoe K., Wakutani Y., Kowa H., et al. Elevated C-reactive protein in patients with vascular dementia. Dement Geriatr Cogn Disord. 2004;17(4): 342-345. doi: 10.1159/000077922.
Smith C.J., Emsley H.C., Gavin C.M., et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004; 4:2. doi: 10.1186/1471-2377-4-2.
Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5): 911-919. doi: 10.1016/j.jaci.2004.12.1100.
Cheng Z., Jiang J., Wu M., et al. Homocysteine-induced inflammation in the vascular endothelium: the role of NF-κB and methylation. Int J Mol Med. 2015;35(2):483-490. doi: 10.3892/ijmm.2014. 2010.
Poddar R., Sivasubramanian N., DiBello P.M., et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation. 2001; 1 03(22):2717-2723.
Tawakol A., Fayad Z.A., Mogg R., et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909-917. doi: 10.1016/j.jacc.2013.04.066.
Undas A., Brummel-Ziedins K., Mann K.G. Plasma and blood clotting are differentially affected by homocysteine. J Thromb Haemost. 2007;5(8):169 7-1704. doi: 10.1111/j.1538-7836.2007.02640. x.
van der Meer I.M., de Maat M.P., Kiliaan A.J., et al. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003; 163(11): 1323-1328. doi: 10.1001/arch-inte.163.11.1323.
Saponsik G., Ray J.G., Sheridan P., et al. Homocysteine-lowering therapy and risk of stroke and other major vascular events in patients with cerebrovascular disease. Meta-analysis of randomized controlled trials. Stroke. 2009;40(7):2422-2428. doi: 10.1161/STROKEAHA.108.541643.
Refsum H., Smith A.D., Ueland P.M., et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004; 50(1): 3-32. doi: 10.1373/clinchem.2003.021 934.
Ridker P.M., Cook N.R. Should C-reactive protein be added to metabolic syndrome and to global risk assessment? Circulation. 2010;122(1):1-2. doi: 10.1161/CIRCULATIONAHA.110.956817.
Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. doi: 10.1161/01.CIR.000005 2939.59093.45.
Zhang W., Sun K., Shen Y., et al. Homocysteine and risk of ischemic stroke: a meta-analysis. J Clin Neurol. 2013;9(1):31-37. doi: 10.3988/jcn.201 3.9.1.31.
Ravaglia G., Forti P., Maioli F., et al. Homocysteine and cognitive function in healthy elderly community dwellers in Italy. Am J Clin Nutr. 2003; 77(3):668-673. doi: 10.1093/ajcn/77.3.668.
Vermeer S.E., van Dijk E.J., Koudstaal P.J., et al. Homocysteine, silent brain infarcts, and white matter lesions: a population-based magnetic resonance imaging study. Ann Neurol. 2002;51(3):285-289. doi: 10.1002/ana.10108.
Di Napoli M., Elkind M.S., Shah I.M., et al. C-reactive protein and outcome after ischemic stroke. Acta Neurol Scand. 2015;132(3):172-181. doi: 10.11 11/ane.12388.
Bustamante A., García-Berrocoso T., Montaner J. Inflammatory and neuroimmunological biomarkers for prognosis in stroke: a review. J Neurochem. 2018;146(5):580-596. doi: 10.1111/jnc.143 57.
Castellanos M., Leira R., Serena J., et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic the-rapy in acute ischemic stroke. Stroke. 2004;35(7): 1671-1676. doi: 10.1161/01.STR.35.7.1671.
Whiteley W., Wardlaw J., Dennis M., et al. The use of blood biomarkers to predict prognosis after acute ischemic stroke: a systematic review and meta-analysis. Cerebrovasc Dis. 2012;33(3):225-23 6. doi: 10.1159/000335632.
Muir K.W., Weir C.J., Alwan W., et al. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30(5):981-986. doi: 10.1161/01.STR.3 0.5.981.
Clarke R., Bennett D., Parish S., et al. Homocysteine-lowering therapy for stroke prevention: a meta-analysis of randomized controlled trials. Lancet Neurol. 2004;3(12):745-753. doi: 10.1016/S147 4-4422(04)70912-1.
Martí-Carvajal A.J., Solà I., Lathyris D., et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8): CD006612. doi: 10.1002/1465185 8. CD006612.pub4.
Schwahn B.C., Chen Z., Laryea M.D., et al. Homocysteine-betaine interactions in a rat model of hyperhomocysteinemia. J Inherit Metab Dis. 2003;26 (1):65-74. doi: 10.1023/A:1023545808741.
Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. doi: 10.1056/NEJ Moa0807646.
Genest J., Libby P. Inflammation and the vascular endothelium: a new target for lipid-lowering therapy? Curr Atheroscler Rep. 2000;2(4):258-264. doi: 10.1007/s11883-000-0012-7.
Esposito K., Marfella R., Ciotola M., et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440-1446. doi: 10.1001/jama.292.1 2.1440.
Ridker P.M., Everett B.M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12): 1119-1131. doi: 10.1056/NEJMoa1707914.